SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending strongly as the stock breaks into new territory, fueled by news related to China's potential export restrictions on rare earth minerals. The community is bullish, anticipating further gains and a potential short squeeze, while also eyeing long-term prospects tied to deep-sea mining and critical mineral demand. Traders are closely watching for news catalysts and technical formations that could drive the stock higher.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver nears a multi-decade high, driven by industrial demand and potential Fed rate cuts, sparking community discussion about a possible breakout. Community members are actively discussing if it will break through the $50 resistance, and some believe a short squeeze is imminent. Some analysts say the stock has more room to run, despite global economic uncertainty.

Aventus Network

Aventus Network ($AVT) is trending, with community members discussing its potential and recent partnerships. Some are pointing to its low market cap and real-world applications in cargo management as reasons for optimism. Mentions of its integration with Polkadot and listing on Coinbase are also circulating.

Global Health Solutions Inc is an American company that works with partners to eliminate diseases that have plagued humanity for centuries and protect the health of populations by helping countries build strong health systems. The private company is located in the US. The company brings together key stakeholders around the world with a common goal to stop diseases and strengthen health systems through powerful partnerships. The company consists of programs and focus areas that cover a range of health issues including neglected tropical diseases, infectious diseases, vaccines, field epidemiology, public health informatics, health workforce development, and health ethics. The company's end goal is to eliminate diseases and protect the health of populations.

Turn Therapeutics Inc.

Turn Therapeutics Inc

Turn Therapeutics ($TTRX) is trending after its recent IPO, with the community discussing its potential for significant gains. Some traders are cautious, pointing to valuation concerns and possible formations on the minute chart, while others see it as the next stock poised for a substantial surge, drawing comparisons to other recent high-flying IPOs.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending as spot silver prices reach new highs, sparking excitement among investors. The community is actively discussing loading up on silver miners and anticipating further gains, drawing comparisons to gold's previous rallies. Some are pointing out the potential for silver miners to go mainstream, while others are debating realistic price targets.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending amidst anticipation for their upcoming Gen AI Summit and Q3 earnings, with investors eager for potential partnership or acquisition news. The community is buzzing about the stock's bullish signals, driven by recent price surges and institutional buying, although some caution against overvaluation based on technical indicators. Discussions also include the fair market value of INOD and its position within the AI data landscape.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express bullish sentiment and long-term commitment to the project, emphasizing the strength and positivity of the WAGMI community. The conversation highlights the community's focus on building and supporting each other, as well as related Solana-based tokens, indicating a broader interest in the ecosystem. Despite some skepticism, many believe WAGMI is poised for significant growth and are encouraging others to join the movement.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending due to increasing community discussion around its potential transition into AI infrastructure, drawing comparisons to early NVIDIA. Bullish sentiment is fueled by growing optimism for the Cayuga site approval and anticipation of a short squeeze, given the high short interest and Google's backing. Some investors highlight TeraWulf's advantageous position in the energy sector, which could be critical for AI data centers, while others point to potential delays and dilution concerns.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as investors speculate about a potential acquisition following increased M&A activity in the metabolic disease space, highlighted by the recent AKRO and MTSR deals. Community discussions revolve around potential buyout offers and the possibility of a short squeeze, with many believing VKTX is undervalued given its pipeline and recent data. The focus is now shifting towards MASH opportunities, adding another layer of potential value for the company.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is trending after reporting strong Q3 earnings, exceeding expectations and raising full-year guidance, boosting investor confidence and lifting the entire airline sector. The community is actively discussing whether to hold or sell, anticipating further gains and a potential rise to new highs. Corporate sales and premium revenue growth reflect strong demand, and the CEO expresses optimism for continued momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Alto Neuroscience (ANRO) soared 54% on Friday afternoon after the company announced that the U.S. Food and Drug Administration granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.Cognitive impairment is a core and disabling feature of Schizophrenia, a serious, disabling mental illness affecting thought, perception, and behavior. According to Alto, there are currently no approved treatments for cognitive impairment associated with schizophrenia.FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A company, whose drug has a Fast Track designation, may be eligible for more frequent meetings with the FDA to discuss the drug’s development plan, as well as for accelerated approval and priority review, subject to the fulfillment of relevant criteria.ALTO-101 is an inhibitor of the PDE4 enzyme that plays a key role in the brain by breaking down a molecule fundamental to learning and memory. By inhibiting the enzyme, the drug seeks to increase the levels of the molecule believed to improve cognitive function.Alto CEO Amit Etkin <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.altoneuroscience.com/news/news-details/2025/Alto-Neuroscience-Receives-FDA-Fast-Track-Designation-for-ALTO-101-for-the-Treatment-of-Cognitive-Impairment-Associated-with-Schizophrenia/default.aspx">termed</a> the designation a significant milestone. “Our Phase 1 data, which demonstrated significant and clinically relevant effects of ALTO-101 on both EEG measures and cognitive performance in healthy subjects, provides strong validation for its mechanism,” he added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANRO">ANRO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:579/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_01_14_PM_png_f2a3fffa4a.webp" alt="ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="579" height="59"><figcaption>ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user highlighted the company’s strong pipeline. Alto is seeking to develop treatments for mental health conditions, including bipolar depression, major depressive disorder, treatment-resistant depression (TRD), and schizophrenia.<stembedurl>https://stocktwits.com/Ccperk/message/630959482</stembedurl>Another user believes the FDA's Fast Track designation is the icing on the cake.<stembedurl>https://stocktwits.com/Ccperk/message/630949029</stembedurl>ANRO stock is up by 61% this year but down by 33% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-reportedly-eyes-door-redesign-to-alleviate-safety-concerns-report/chCuVXzR3QQ">Rivian Reportedly Eyes Door Redesign To Alleviate Safety Concerns: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

Equity

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.


Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO

Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO Alto Neuroscience, Inc. Sued for Securities Law Violations...

1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March

Alto Neuroscience represents a high-risk, high-reward opportunity.

Alto Neuroscience Inc. has struggled recently, with shares losing more than 12% over the past week, extending a decline that began in late October following disappointing Phase 2&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anro-stock-crashes-premarket-after-drug-trial-fails/cJ2L0NwReH">results</a> for its major depressive disorder (MDD) treatment, ALTO-100.&nbsp;Despite the stock sliding over 34% this year, it has not lost appeal among retail traders as Alto's follower count on Stocktwits has surged 44.6% in the past week.&nbsp;Over the last year, its retail following on the platform has grown by an astonishing 876%, suggesting that traders remain interested in the company's long-term prospects.Alto is developing treatments for central nervous system diseases and has positioned its biomarker-driven approach as a differentiator in psychiatric drug development.&nbsp;While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.&nbsp;Last month, Alto announced that a planned interim analysis of the trial had a favorable outcome, prompting the company to expand the study by approximately 50 biomarker-positive patients. Topline results from the trial are expected in mid-2026.&nbsp;The company also secured a U.S. patent for ALTO-300, covering its use as an adjunctive treatment for MDD patients who have not responded adequately to traditional antidepressants.&nbsp;The patent also includes methods for identifying eligible patients using EEG-based biomarker selection, which Alto sees as a key advantage in developing more targeted psychiatric treatments.<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ANRO_sentiment_and_message_volume_as_of_Feb_28_3028c3e1a2.png" alt="ANRO sentiment and message volume as of Feb 28.png" width="1316" height="316"><figcaption>ANRO sentiment and message volume as of Feb 28 vs a week ago | source: Stocktwits</figcaption></figure>Retail traders on Stocktwits have pointed to several potential catalysts, including reports that Jefferies sees a 500% upside for the stock.&nbsp;Some investors have also highlighted Alto's financial position, noting that the company is trading near 40% of its cash value while holding two Phase 3-ready assets and no debt.<stembedurl>https://stocktwits.com/Eternallybullish1988/message/606427653</stembedurl><stembedurl>https://stocktwits.com/BossTrade/message/606325236</stembedurl>Jones Research maintained a 'Buy' rating with an $18 price target in December, arguing that the market reaction to ALTO-100's failure was overdone.&nbsp;Last week, Alto said it would participate in a series of upcoming industry conferences in March, including the TD Cowen 45th Annual Health Care Conference, Leerink's Global Healthcare Conference, and the Stifel 2025 Virtual CNS Forum.&nbsp;With attention now focused on the ALTO-300 trial and upcoming investor events, retail investors will be hoping market sentiment around the stock tilts back into the bullish zone.Alto stock is rated ‘buy’ among six out of seven analysts covering the stock on Wall Street, with one rating ‘hold’, according to Koyfin data.Short interest, meanwhile, has edged down from 15.1% at the start of this year to 14.7% as of the end of last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 

Why Micro-Cap Alto Neuroscience's Retail Following On Stocktwits Surged Nearly 45% Last Week

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 


Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the...

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple...

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline Allink Biotherapeutics Raises $42M Series A Financing to Accelerate...

Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial...

ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alto Neuroscience, Inc. (Alto Neuroscience or the Company) (NYSE: ANRO...

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$6.25
Prev Close	$6.21
Open	$6.25
Dividend Yield	0.00%
50-Day Moving Average	$3.85
Beta	1.50
Avg. Volume	79,206.71
PE Ratio	-2.59

52-Week High	$15.04
52-Week Low	$1.60
Market Capitalization	$168.15M
EPS (Annual)	-$2.50
Price to Book	1.36
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ANRO
Alto Neuroscience Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANRO News

ANRO Alto Neuroscience Inc.